Clinical trials
Recurrent Ovarian Cancer clinical trials
Below are recruiting recurrent ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 227 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT07167433Recruiting
Observational study of ovarian cancer from 2021 onward
This study looks at the real-world experiences of patients with ovarian cancer, whether newly diagnosed or with persistent or recurrent disease. It aims to learn more about the disease and its treatment over time.
Barretos/SPAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT05740956RecruitingPhase 1
Drug study for cancers with HRR gene or HRD changes
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
Beijing, Beijing MunicipalityAges 18–75 - NCT05927818Recruiting
Test a sentinel lymph node biopsy in early ovarian cancer
This trial studies whether taking a sample from the sentinel lymph node during surgery can help with staging early ovarian cancer. It may help doctors find spread to lymph nodes more accurately while limiting unnecessary lymph node removal in some cases.
Istanbul, TurkeyAges 18–90 - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT07702292RecruitingPhase 2
68Ga-BED003 PET scan for certain cancers
This trial tests a new PET imaging agent that targets a protein called FAP, which appears in many solid tumors. The goal is to see if this scan can better find and measure cancer in the body.
Bergamo, LombardyAges 18–79 - NCT07432633RecruitingPhase 1/Phase 2
Imaging scan to detect cancer-linked protein in several tumor types
This trial tests a new PET scan tracer that targets a protein found on certain cancer cells. It may help doctors better see and understand tumors in people with colorectal, gastric, pancreatic, lobular breast, or ovarian cancer.
Dallas, TexasAges 18–80 - NCT07604766RecruitingPhase 3
Rina-S for platinum-resistant ovarian cancer in China
This study tests a new cancer drug called Rina-S (an antibody-drug conjugate, which is a targeted therapy that delivers medicine directly to cancer cells) compared to standard treatment options for ovarian cancer that has returned or worsened after platinum chemotherapy. The trial is specifically for patients in China whose cancer is resistant to platinum drugs.
ChangchunAges 18 years+ - NCT06234423RecruitingPhase 1
A study of CUSP06 for advanced solid tumors
This study tests a new drug called CUSP06 for people with advanced solid tumors, especially ovarian cancer that has stopped responding to platinum chemotherapy. It may help if standard treatments no longer work.
Denver, ColoradoAges 18 years+ - NCT07050771RecruitingPhase 2
Prehabilitation before cancer surgery study
This trial tests a comprehensive program of exercise, nutrition, and wellness support before and after major cancer surgery. It aims to help patients recover faster and better, whether or not they also receive chemotherapy or radiation before surgery.
Houston, TexasAges 18 years+ - NCT05104515RecruitingPhase 1
First cancer vaccine test for advanced lung, ovarian, or prostate cancer
This Phase 1 study tests OVM-200, a new cancer vaccine, to see how it is tolerated and how it affects the immune system in people with advanced NSCLC, ovarian cancer, or prostate cancer. You may be eligible if your cancer has already had approved treatment(s) and no further standard options are planned within the first two months.
London, LondonAges 18–75 - NCT05123482RecruitingPhase 1/Phase 2
Study of an experimental drug for advanced solid tumors
This trial tests a new drug, called AZD8205, alone or with other medicines, for people with advanced or metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or slow their growth.
Duarte, CaliforniaAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Birmingham, AlabamaAges Any age - NCT07708753RecruitingPhase 3
Study of a new drug for advanced ovarian cancer that stopped responding to platinum
This study tests a new drug called SYS6043 for advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. It aims to see if this drug can help when other treatments have not worked.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05329532RecruitingPhase 1/Phase 2
Modi-1 cancer vaccine for several hard-to-treat cancers
This Phase 1/2 study tests a cancer vaccine called Modi-1 Moditope in people with advanced triple-negative breast cancer, head and neck cancer, ovarian/high-grade serous cancer, or kidney cancer. It aims to help the immune system better recognize and attack the cancer.
Brighton, DefaultAges 18 years+ - NCT06817694Recruiting
CBT for fear of cancer returning in BRCA1/2 women
This trial tests if cognitive behavioral therapy can reduce fear of cancer recurrence in women with BRCA1/2 mutations who have finished treatment for breast or ovarian cancer. It aims to help you cope with worries about cancer coming back.
Québec, QuebecAges 18 years+ - NCT05103683RecruitingPhase 1
First-time test of TORL-1-23 for advanced solid tumors
This early study tests a new drug (TORL-1-23) in people with advanced solid cancers. It aims to find the safest dose and see how the tumor responds.
Fullerton, CaliforniaAges 18 years+ - NCT05704621RecruitingPhase 2
Surgery after PARP inhibitor failure in returning ovarian cancer
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
SeoulAges 18 years+ - NCT06617923RecruitingPhase 2
Senaparib and Temozolomide for ARID1A-Mutated Ovarian Cancer
This trial tests a combination of two drugs, senaparib and temozolomide, for women with a specific type of ovarian cancer that has come back or is resistant to platinum-based chemotherapy. It is for patients whose tumor has a change in the ARID1A gene.
Baltimore, MarylandAges 18 years+ - NCT07489287RecruitingPhase 1
GB-5267 for platinum-resistant ovarian, peritoneal, or fallopian tube cancer
This trial tests a new cell therapy (GB-5267) for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. It requires multiple tumor biopsies and aims to see if the treatment can help when standard chemo stops working.
Buffalo, New YorkAges 18 years+ - NCT07407062Recruiting
Study of folate receptor alpha in ovarian cancer tissue
This study looks at a marker called folate receptor alpha in tissue samples from people with ovarian, fallopian tube, or primary peritoneal cancer that has returned. The goal is to see how common this marker is, which may help guide future treatment options.
Rome, RomaAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Birmingham, AlabamaAges 18–60 - NCT04590326RecruitingPhase 1/Phase 2
Study of REGN5668 with or without immunotherapy in ovarian cancer
This Phase 1/2 study tests how safe REGN5668 is and how well it works in adult women with advanced gynecologic cancers. It compares REGN5668 given with cemiplimab alone, or cemiplimab plus fianlimab, and looks for responses in tumors that meet specific criteria.
Duarte, CaliforniaAges 18 years+
Hear when a new Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent ovarian cancer?
- Yes. Clin2 currently lists 227 recruiting recurrent ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.